Patients
PDAC
DISEASE PROGRESSION, DISEASE, DIABETES MELLITUS, CENTRAL NERVOUS SYSTEM METASTASES, ONCOLOGY
Eligible patients were ≥18 years of age with metastatic PDAC and disease progression following 1 or 2 prior lines of therapy. Patients were required to have measurable disease as defined by RECIST v1.1, an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1, adequate organ function, and be considered appropriate candidates for single‐agent chemotherapy with capecitabine or gemcitabine. Patients with insulin‐dependent diabetes mellitus, symptomatic central nervous system metastases, or those previously treated with CDK4/6, PI3K, and/or mTOR inhibitors were not eligible.The study protocol was approved by the appropriate institutional review boards and ethics committees and conducted in accordance with the Good Clinical Practice of the Declaration of Helsinki. All patients provided written informed consent. Patients were enrolled at 32 sites in 8 countries.